What is the catalog number for VAL-083?

The catalog number for VAL-083 is HY-16513.

What sizes are available for VAL-083?

VAL-083 is available in the following size(s): 5 mg, 10 mg, 10 mM - 1 mL, 50 mg, 100 mg.

How many pack sizes does VAL-083 come in?

VAL-083 is available in 5 different pack sizes.

VAL-083 is currently made to order / not held in immediate stock. Contact us for lead time.

Who manufactures VAL-083?

VAL-083 is manufactured by QuantiMol.

What is the estimated delivery time for VAL-083?

Estimated delivery time for VAL-083 is approximately 15 business day(s), depending on your location.

Where can I find the safety data sheet (SDS/MSDS) for VAL-083?

The safety data sheet for VAL-083 is available here: http://file.medchemexpress.com/batch_PDF/HY-16513/VAL-083-SDS-MedChemExpress.pdf.

VAL-083

VAL-083 is an alkylating agent that creates N7 methylation on DNA, with antitumor activity.

Product Specifications

CAS Number

23261-20-3

Product Name Alternative

Dianhydrodulcitol; Dianhydrogalactitol

UNSPSC

12352005

Target

DNA Alkylator/Crosslinker

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/val-083.html

Purity

98.0

Solubility

H2O : 70 mg/mL (ultrasonic)

Smiles

O[C@H]([C@H](O)[C@]1(OC1)[H])[C@@]2([H])CO2

Molecular Formula

C6H10O4

Molecular Weight

146.14

References & Citations

[1]Kaiji Hu, et al. Abstract 811: VAL083, a novel N7 alkylating agent, surpasses NSC 362856 activity and inhibits cancer stem cells providing a new potential treatment option for glioblastoma multiforme. Cancer Research. 2012 Mar 31-Apr 4.|[2]Jiang X, et al. Dianhydrogalactitol, a potential multitarget agent, inhibits glioblastoma migration, invasion, and angiogenesis. Biomed Pharmacother. 2017 Jul;91:1065-1074.|[3]Peng C, et al. 1,2:5,6-dianhydrogalactitol inhibits human glioma cell growth in vivo and in vitro by arresting the cell cycle at G2/M phase. Acta Pharmacol Sin. 2017 Apr;38 (4) :561-570.